Electra Therapeutics priced and launched an upsized IPO, raising $350 million on Nasdaq as investors look for a pipeline boost in inflammation. The proceeds are earmarked for advancing ipsoprubart, a pan-SIRP monoclonal antibody, through phase II/III toward a potential biologics license application in secondary hemophagocytic lymphohistiocytosis (sHLH).